Expression of Peripheral Blood microRNA ‐126 and Its Prognostic Value in Patients With Acute Myeloid Leukemia
International Journal of Laboratory Hematology · 2026-12 · 48 (6) · 1405-1417
DOI: 10.1111/ijlh.70211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 06.08.2026. Verfasst von Haiying Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, China. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Myeloid, Acute, Biomarkers, Tumor, Gene Expression Regulation, Leukemic. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to characterize peripheral blood microRNA (miR)‐126 expression and evaluate its prognostic significance in patients with acute myeloid leukemia (AML).
Methods
AML patients ( n = 78) and healthy volunteers ( n = 81) were enrolled in this retrospective study as the AML and Control groups. Clinical data were collected, and peripheral blood miR‐126 expression was measured by RT‐qPCR. Receiver operating characteristic (ROC) curves assessed the prognostic value of miR‐126. Kaplan–Meier analysis compared survival outcomes between patients with high and low miR‐126 expression. Univariate and multivariate Cox regression analyses were conducted to determine whether miR‐126 was an independent risk factor for overall survival (OS) and progression‐free survival (PFS).
Results
Peripheral blood miR‐126 expression was significantly higher in the AML group than in controls [1.30 (0.51–2.30) vs. 0.42 (0.30–0.62)]. The area under the ROC curve (AUC) of miR‐126 to distinguish AML patients from healthy controls was 0.815, with 62.82% sensitivity and 93.83% specificity at a cutoff value of 0.86. Patients with high miR‐126 expression had higher proportions of extramedullary infiltration and high‐risk European LeukemiaNet classification and significantly shorter OS and PFS. The AUC of miR‐126 for predicting poor prognosis was 0.796, with 73.20% sensitivity and 75.70% specificity at a cutoff value of 1.297. After adjustment, miR‐126 was confirmed as an independent predictor of reduced OS and PFS.
Conclusion
Elevated peripheral blood miR‐126 expression is associated with reduced OS and PFS of patients with AML and may serve as a useful biomarker for prognostic assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, China.
- Jiangxi Health Commission Key Laboratory of Leukemia, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, China.
ORCID-Profile: Mingxing Zhong
Zitieren
APA
Zhang, H., Zhang, H., Xia, L., Chen, Y., Chen, C., He, D., Zhong, Z., Wen, C., Liu, D., & Zhong, M. (2026). Expression of Peripheral Blood microRNA ‐126 and Its Prognostic Value in Patients With Acute Myeloid Leukemia. International Journal of Laboratory Hematology, 48(6), 1405-1417. https://doi.org/10.1111/ijlh.70211
Vancouver
Zhang H, Zhang H, Xia L, Chen Y, Chen C, He D, et al. Expression of Peripheral Blood microRNA ‐126 and Its Prognostic Value in Patients With Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2026;48(6):1405-1417. doi:10.1111/ijlh.70211
BibTeX
@article{Zhang2026,
author = {Zhang, Haiying and Zhang, Huaqing and Xia, Lingzhou and Chen, Yuting and Chen, Changkun and He, Dong and Zhong, Zhiqiang and Wen, Chunju and Liu, Dongting and Zhong, Mingxing},
title = {Expression of Peripheral Blood microRNA ‐126 and Its Prognostic Value in Patients With Acute Myeloid Leukemia},
journal = {International Journal of Laboratory Hematology},
year = {2026},
volume = {48},
number = {6},
pages = {1405--1417},
doi = {10.1111/ijlh.70211}
}
EUVIMED